The therapeutic potential of targeting YAP/TAZ and related signaling molecules such as Wnt5A, ET-1, AREG, and ECM components offers promising avenues for improving outcomes in ovarian cancer patients. This evidence concerns the gene WNT5A and ovarian carcinoma.